Antisense oligonucleotides for the treatment of dyslipidaemia
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Antisense oligonucleotides (ASOs) are short synthetic analogues of natural nucleic acids designed to specifically bind to a target messenger RNA (mRNA) by Watson-Crick hybridization, inducing selective degradation of the mRNA or prohibiting translation of the selected mRNA into protein. Antisense technology has the ability to inhibit unique targets with high specificity and can be used to inhibit synthesis of a wide range of proteins that could influence lipoprotein levels and other targets. A number of different classes of antisense agents are under development. To date, mipomersen, a 2'-O-methoxyethyl phosphorothioate 20-mer ASO, is the most advanced ASO in clinical development. It is a second-generation ASO developed to inhibit the synthesis of apolipoprotein B (apoB)-100 in the liver. In Phase 3 clinical trials, mipomersen has been shown to significantly reduce plasma low-density lipoprotein cholesterol (LDL-c) as well as other atherogenic apoB containing lipoproteins such as lipoprotein (a) [Lp(a)] and small-dense LDL particles. Although concerns have been raised because of an increase in intrahepatic triglyceride content, preliminary data from long-term studies suggest that with continued treatment, liver fat levels tend to stabilize or decline. Further studies are needed to evaluate potential clinical relevance of these changes. Proprotein convertase subtilisin/kexin-9 (PCSK9) is another promising novel target for lowering LDL-c by ASOs. Both second-generation ASOs and ASOs using locked nucleic acid technology have been developed to inhibit PCSK9 and are under clinical development. Other targets currently being addressed include apoC-III and apo(a) or Lp(a). By directly inhibiting the synthesis of specific proteins, ASO technology offers a promising new approach to influence the metabolism of lipids and to control lipoprotein levels. Its application to a wide variety of potential targets can be expected if these agents prove to be clinically safe and effective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671 · cited 1×
“In addition, an extensive body of evidence, including a number of so-called Mendelian randomization studies, has now substantiated that an elevated Lp(a) level is a major and independent CVD risk factor.(38) However, evidence that lowering Lp(a) levels is beneficial with respect to CVD prevention is not yet available,…”
BackgroundPollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., et al. (2008) · Science · doi:10.1126/science.1161524 · Cited by 688 · cited 1×
“Genetic studies in humans have associated lower levels of apoC-III with lower triglyceride levels possibly with improved health and extended longevity.(37) In animal models, the administration of apoC-III ASOs resulted in reductions in plasma triglyceride levels of 40–60%.”
BackgroundInhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia
Cuchel, M., Bloedon, L. T., Szapary, P. O., Kolansky, D. M., Wolfe, M. L., Sarkis, A., Millar, J. S., Ikewaki, K., Siegelman, E. S., Gregg, R. E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061189 · Cited by 580
Zaid, A., Roubtsova, A., Essalmani, R., Marcinkiewicz, J., Chamberland, A., Hamelin, J., Tremblay, M., Jacques, H., Jin, W., Davignon, J., et al. (2008) · Hepatology · doi:10.1002/hep.22354 · Cited by 404
Merki, E., Graham, M., Taleb, A., Leibundgut, G., Yang, X., Miller, E. R., Fu, W., Mullick, A. E., Lee, R., Willeit, P., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.10.052 · Cited by 124 · cited 1×
“Early preclinical studies suggest that targeting liver expression of apo(a) with ASOs directed to KIV-2 repeats—which are expressed in multiple copies in the human apo(a) gene—may provide a highly effective approach to lower elevated Lp(a) levels in humans.(39) The development of such ASOs to lower Lp(a) levels might…”
BackgroundSelf-citationHepatic and Cardiovascular Consequences of Familial Hypobetalipoproteinemia
Sankatsing, R. R., Fouchier, S. W., de Haan, S., Hutten, B. A., de Groot, E., Kastelein, J. J. P., & Stroes, E. S. G. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000176191.64314.07 · Cited by 106 · cited 1×
“On the other side of the spectre, in patients with familial hypobetalipoproteinaemia (FHBL), characterized by genetically determined very low apoB levels, the CVD rate is very low.(5,6) In many of these subjects, the very low LDL-c levels are caused by truncation mutations in apoB, which leads to impaired hepatic secr…”
BackgroundSelf-citation
Cited by
Antisense technology: an overview and prospectus
Crooke, S. T., Baker, B. F., Crooke, R. M., & Liang, X.-H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00162-z · Cited by 775
Watts, G. F., Gidding, S., Wierzbicki, A. S., Toth, P. P., Alonso, R., Brown, W. V., Bruckert, E., Defesche, J., Lin, K. K., Livingston, M., et al. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.11.025 · Cited by 377
Self-citationNew therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs
Norata, G. D., Ballantyne, C. M., & Catapano, A. L. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht088 · Cited by 99
Minicocci, I., Santini, S., Cantisani, V., Stitziel, N., Kathiresan, S., Arroyo, J. A., Martí, G., Pisciotta, L., Noto, D., Cefalù, A. B., et al. (2013) · Journal of Lipid Research · doi:10.1194/jlr.p039875 · Cited by 97
Apolipoprotein C-III: Going Back to the Future for a Lipid Drug Target
Huff, M. W., & Hegele, R. A. (2013) · Circulation Research · doi:10.1161/circresaha.113.301464 · Cited by 70
Novel strategies for managing dyslipidemia: treatment beyond statins
Ling, H., Burns, T. L., & Hilleman, D. E. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.11.2612 · Cited by 10
Metadata
- Authors
- Visser, M. E., Witztum, J. L., Stroes, E. S. G., & Kastelein, J. J. P.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-05-24
- Volume
- 33
- Issue
- 12
- Pages
- 1451-1458
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2168836317
- Cited by
- 103
- References
- 6
- FWCI
- 18.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.